Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

NCT05702853 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

B-cell Non Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: Cyclophosphamide injection
DRUG: Fludarabine Injection
BIOLOGICAL: CD19-CD34t metabolically programmed CAR transduced T-cells

Sponsor

Medical University of South Carolina